NASD · Healthcare · Biotechnology · USA
Rhythm Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Rhythm Pharmaceuticals develops therapies for rare neuroendocrine diseases marked by severe obesity and hyperphagia caused by MC4R pathway dysfunction. Its lead product, IMCIVREE (setmelanotide), treats obesity from Bardet-Biedl syndrome and certain genetic deficiencies in the United States and European Union. The company also develops bivamelagon and RM-718, investigational MC4R agonists for hypothalamic obesity and Prader-Willi syndrome.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Rhythm Pharmaceuticals Inc stock.
Overvalued: intrinsic value $8.95 per share, market price $116.61, margin of safety -1202.7% (as of 2026-11-17).
A 2.4x revenue multiple, discounted for its losses, values the shares at $8.95; the price of $116.61 is 1203% above that value.
17 more funds hold it; the full list is part of the paid plan.
109 more in this industry show a wider margin of safety.
RYTM is overvalued (as of the 2026-11-17 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $8.95; the price of $116.61 is 1203% above that value.
$8.95 per share (as of the 2026-11-17 close), against a market price of $116.61. That is a margin of safety of -1202.7%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.